Hillhurst Biopharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.hillhurstbio.com
Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 2
1 (33.3%)Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
Phase 2
Not yet recruiting
- Conditions
- Parkinson Disease
- Interventions
- Drug: Vehicle (placebo)
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Hillhurst Biopharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT07005180
A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Hillhurst Biopharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT06144749
- Locations
- 🇵🇦
Cevaxin - The Panama Clinic, Panama City, Panama
🇵🇦Hospital Pacífica Salud, Panama City, Panama
A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Hillhurst Biopharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03926819
- Locations
- 🇺🇸
Contact Company, San Diego, California, United States
News
No news found